{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:51:51Z","timestamp":1768405911477,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jiac.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T19:17:28Z","timestamp":1685819848000},"page":"895-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-8033","authenticated-orcid":false,"given":"Shoji","family":"Kubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Shinkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-7640","authenticated-orcid":false,"given":"Kohei","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.06.002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114925","article-title":"In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)","volume":"96","author":"Karlowsky","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jiac.2018.10.012","article-title":"The efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections","volume":"25","author":"Mikamo","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.06.002_bib4","article-title":"Pharmaceutical safety and environmental health bureau, Ministry of health, labour and Welfare. Guideline for the clinical evaluation of antibitotis","volume":"1023\u20133","author":"Pharmaceutical Evaluation Division","year":"2017","journal-title":"PFSD\/ELD Notification No."},{"key":"10.1016\/j.jiac.2023.06.002_bib5","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12941-022-00528-0","article-title":"Ceftolozane\/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)","volume":"21","author":"Khankhel","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiac.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The surgical infection society revised guidelines on the management of intra \u2500 abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg Infect"},{"key":"10.1016\/j.jiac.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.03074-15","article-title":"Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study","volume":"60","author":"Miller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23001381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23001381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:04Z","timestamp":1761159964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1341321X23001381"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.06.002","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}